Begoña Bermejo de Las Heras

15PUBLICATIONS
230CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Sep 17, 2026
Longitudinal Clinical, Physiological, and Molecular Profiling of Female Patients With Metastatic Cancer: Protocol and Feasibility of a Multicenter High-Definition Oncology Study.

|Aug 24, 2026
Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE.

|May 10, 2026
Expert consensus on optimal management of liver-related adverse events during CDK4/6 inhibitor therapy.

|Apr 24, 2026
Maximizing the impact of real-world evidence on cancer treatment: what do we need to achieve it?

|Dec 12, 2025
Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2- Highly Proliferative Breast Cancer.

Miguel Martín, Ángel L Guerrero-Zotano, María E Pérez-López

|Aug 11, 2025
Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1.

Richard D Baird, Begoña Bermejo de Las Heras, Manuel Ruiz-Borrego

Pageof 3

Frequent Collaborators

6 joint publications

Manuel Ruíz-Borrego

6 joint publications

Eva Maria Ciruelos Gil

5 joint publications

Miguel J Gil-Gil

4 joint publications

Miguel Martín